ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Ibuprofen"

  • Abstract Number: 048 • 2023 Pediatric Rheumatology Symposium

    Comparative Efficacy and Safety of Ibuprofen and Naproxen in the Treatment of Oligoarticular Juvenile Idiopathic Arthritis (oJIA): Bi-national Cohort Study

    Orly Ohana1, Itay Marmor2, Liora Harel3, Shiri Rubin4, rotem tal5, Yoel Levinsky6, Orit Peled7 and Gil Amarilyo3, 1Pediatric C ward, Schneider Children's Medical Centre, Petach Tikva, Israel, 2Dana-Dwek Children's Hospital, Hod Hasharon, Israel, 3Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel, 4Pediatric Ear Nose and Throat Unit Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, 5Schneider Children's Medical Center of Israel, Petach Tikva, Israel, 6Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, 7Department of Pharmacy, Schneider Children's Medical Center of Israel, Petach Tikva, Israel

    Background/Purpose: JIA is the most common childhood rheumatic disease. NSAIDs and intraarticular corticosteroid injections (IACI) are first-line therapy for oJIA. NSAIDs Adverse events (AEs) include…
  • Abstract Number: 2433 • 2014 ACR/ARHP Annual Meeting

    Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac for Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

    Fabiola Atzeni1,2, Alessandra Monguzzi3, Elisabetta Grillo3, Luigi Lanata3 and Piercarlo Sarzi-Puttini2, 1V Giovanni Battista Grassi 74, Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, 2Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, 3Medical Department, Dompé SpA, Milan, Italy

    Background/Purpose: Patients with rheumatic diseases, including rheumatoid arthritis (RA), describe symptoms such as pain and stiffness as important factors affecting their quality of life. The…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology